White Paper

Clinically Proven LipoAvail® NAD Better Absorption

Overview

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and efficacy.

LipoAvail® NAD+ offers the only clinically validated liposomal NAD+ on the market. Our clinical study shows that the LipoAvail® NAD+ group demonstrated 1.52 times higher NAD+ bioavailability compared to the regular NAD+ group. Meaning more NAD+ can be absorbed by your body for enhanced efficacy!

Download the Liposome White Paper to learn about industry trends; contact us for the study details and discover more clinically backed liposomal products.

This content is provided by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for and content provided by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for and content provided by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”

Related Resources

Your Product Innovation Begins Here: Booth 3G84

30-Apr-2025

Content provided by Effepharm Ltd

Product Brochure

This year’s Vitafoods EU, EffePharm will showcase innovative anti-aging solutions, featuring Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand.